Summary When cyclophosphamide (CY) (100-120 mg kg-') was administered intravenously (i.v.) to normal F-344 rats, oliguria occurred over the 5-day observation period. Conversely, in rats bearing matrix metalloproteinase-9 (MMP-9) producing 1 3762NF mammary adenocarcinoma (MTLn3 clone), polyuria occurred chiefly during the first 24 h after CY treatment. In parallel with urine volume, a decrease in the urinary excretion of Nacetyl-beta-D-glucosaminidase (NAG) was observed during the first 5 days after CY treatment in normal rats, but it increased in MTLn3-bearing rats. No elevation in blood urea nitrogen (BUN) or serum creatinine (Cr) values was observed for either group. Both urine volume and urinary excretion of NAG after CY treatment were lower in rats bearing the MTC clone (lower production of MMP-9) than for those bearing the MTLn3 clone. In the case of treatment with cisplatin (CDDP, 4-6 mg kg-'), urine volume, urinary NAG excretion and BUN and serum Cr values all increased in normal rats and were all found to be higher in MTLn3-bearing rats than in normal rats. The diuretic response to these drugs in tumour-bearing (TB) rats may be associated with MMP-9 produced by the tumour cells. This report suggests that the nephrotoxicity due to anti-cancer drugs may change when the drugs are used for the treatment of patients bearing a MMP-9-producing tumour.
process in tumour invasion and metastasis. The close association between the metastatic potential of tumour cells and activities of extracellular matrix degradative enzymes has been reported in a varietx of malignant tumours (Liotta et al. 1980 . 1990 : Levy et al. 1991 : Yamagata et al. 1991 : Stetler-Stesenson et al. 1993 : Zucker et al. 1993 : Gohji et al. 1994 -. Among several matrix metalloproteinases (MMPs). MMP-7. MMP-9 and MT-MMP are reported to be representative of the ones which the tumour itself produces.
While carrying out experimental chemotherapy using an MMP-9-producing tumour (13762NF. MTLn3 clone) in rats. ve came up with the simple question of how the toxic side-effects of anticancer drugs would be modified in hosts bearing MMPsproducing tumours. As no studx could be found to answer our question. vie initiated our own experiments on rats. At first. we planned to define the influence of MMP-9 on cyclophosphamide (CY -induced haemorrhagic cystitis (Philips et al. 1961 : Meisenberg et al. 1994 ) and started to measure the haemoglobin le,vel in urine. In the course of the experiments. we found a large discrepancy in urine volume between normal and MTLn3-bearing rats after CY treatment. In this report. wve demonstrate that nephrotoxicity. as a result of treatment by cvclophosphamide (CY) or cisplatin (CDDP). may be radically modified in hosts bearing MMPs-producing tumours. 
Tumours
The 1 3762NF tumour is a mammar-adenocarcinoma derixved from a F-344 rat. The MTC clone was established from a local mammar-fat pad site and MTLn3 from a spontaneous lung metastasis site. both of wvhich were kindlv donated bv Dr GL Nicolson (USA). The MTLn3 clone produces a larger amount of MMP-9 and is more metastatic than the MTC clone (Nakajima et al. 1987 (Nakajima et al. . 1993 MMP-9-prodLucing tumour and CY-induced nephrotoxicity 1031 Collection of urine and blood Each rat was kept in a metabolic cage and urine was collected at 24-h intervals for 5 days. Blood was collected from the tail vein and the sera were analvsed.
Measurement of N-acetyl-beta-o-glucosaminidase (NAG) activity NAG activitv in urine was measured by the colorimetric assax using NAG Rate Test Shionogi (Shionogi. Japan) (Noto et al. 1983 When CY (100 mg kg-') was administered i.x. to normal rats. their unne volume during the first 24 h decreased from 6.9 ml to 3.7 ml. Converselv. in MTLn3-bearing rats. polyuria occurred dungn the first 24 h after CY treatment: unrne volume was 34.7 ± 8.4 ml for tumour-bearing rats on dav 14 (TB-14 rats) and 19.6 ± 2.0 ml for TB-21 rats ( Figure IA) . Specific gravity of the unrne was 1.038 ± 0.004. 1.063 ± 0.003 and 1.014 ± 0.002 for the normal control rats. CY-treated non-TB rats and CY-treated TB-14 rats respectively. There was no significant diference in urine volume between normal and TB rats up to 21 days after tumour inoculation.
Following CY treatment. oliguria in normal rats and polyuria in TB rats became apparent when their 5-d urine volumes were compared ( Figure 1B ). Five-day urine volume taken after CY (100 mg kg-1) treatment decreased from 22.1 ± 1.6 ml to 7.6 ± 1.1 ml (P < 0.001) for normal rats. but it showed an increase to 58.5 ± 9.5 ml (P < 0.01 ) for TB-14 rats. Similar findings were also observed in the unrne volumes with the administration of 120 mg kg-' of CY. but not for 80 mg kg-I CY.
Urinarv NAG excretion was measured to assess the renal tubular damage ( Figure 2 ) (Naruse et al. 1981 : Valentovic et al. 1994 . NAG excretion (5 davs) after CY ( 100-120 mg kg-' ) treatment was significantly lower in non-TB rats than in normal control rats. and was significantly higher in TB rats than in normal control and non-TB rats. CY. at a dose of 80 mg kg-'. did not cause any significant changes in urinarv NAG excretion in normal and TB rats.
Changes in biochemical substances in sera after tumour inoculation are shown in Table 1 on day 42 after tumour inoculation (Table 2 ). In MTC-bearing rats. unne volume and urinarv NAG excretion after CY treatment were higher than in normal rats. but lower than in MT1-n3-bearing rats.
Nephrotoxic effect of CDDP Nephrotoxicity from CDDP is well known (Mizushima et al. 1987 : Meyer and Madias. 1994 : Leibbrandt et al. 1995 . Thus. we compared the nephrotoxic effect of CY with that of CDDP (at levels of 4 and 6 mg kg-') in F-344 rats. In contrast to CY. a diuretic response occurred in normal rats after CDDP treatment:
Britsh Joumal of Cancer (1998) 78(8) urine Xolume (nml per 5 days) increased from 22.1 ml to 30.8 ml for 4 mg kg-I CDDP and to 33.5 ml (P < 0.05) for 6 mg kga-' of CDDP ( Figure 3 ). Urinary NAG excretion (x I0-U per 5 days) also increased from 391 to 653 (P < 0.05) for 4 mg kg-' CDDP and to 670 (P < 0.05) for 6 mg kg-' (Table 3 ). These increases w-ere all larger in the TB (MTLn3)-14 rats than in non-TB rats. BUN and Cr values also tended to be higher in the TB (NMTLn3 -l4 rats than in non-TB rats.
DISCUSSION
We have shown in this study that there wVas a large discrepancy in urine X olume between normal rats and rats bearing MMP-9-producina tumour after CY treatment. Nephrotoxicity due to CY and its analoaue of ifosfamide has been well documented in both man and animals (Lopes. 1967 : Lavin and Koss. 1970 : Goren et al. 1987 : Henev et al. 1989 : Patterson and Khojasteh. 1989 . After (TB-19). As a control, non-TB rats were used (N-5). Each group consisted of 5-7 rats. bp < 0.01, cP < 0.001 vs the normal group. T-P. total protein; GOT. much larger in rats bearing the MTLn3 clone (high production of MMP-9) than in rats bearing the MTC clone (low production of MMP-9) also seems to support this speculation. Clinically. nephrotoxicity from CDDP is more common than that from CY. and the occurrence of proximal tubular necrosis in CDDP-treated rats has been well documented (Safirsten et al. 1986 : Wolfgang et al. 1994 : al-Harbi et al. 1995 . Therefore. we also examined the nephrotoxic effect of CDDP in TB rats. There were some differences in nephrotoxicity between CY and CDDP In normal rats. poly-uria and marked elevations of BLJN and Cr occurred after CDDP. which were not observed with CY. These indices were further enhanced in MTLn3-bearing rats than for non-TB rats. which also sugrgests that MMP-9 might enhance the renal toxicity due to CDDP. Early polyuria following CDDP administration is well documented. Clifton et al (1982) reported that the CDDP-induced polyuria was caused by the inhibition of antidiuretic hormone (ADH) release. but Daugaard et al (1986) stated that this possibility seemed unlikely. Ohta et al (1991) reported that production of endothelin. a mediator of renal v-asoconstriction. could be associated with the CDDP nephrotoxicity. More detailed studies will be required to define the mechanism. Type IV collagenolytic activity was detected in plasma from MTLn3-bearing, rats by means of zymography in our laboratory. as already shown by Nakajima et al (1993) . MMPs activities are regulated by the tissue inhibitors of metalloproteinases (TIMP-1. TIMP-2) (Kodama et al. 1989 : Boone et al. 1990 ). We speculate that MMP-9 is responsible for some reactions taking place in viVo in TB hosts. However. the augmentation of side-effects by anticancer drugs in MMP-9-bearinr hosts seems to relate to organs.
In preliminary experiments. we examined the hepatotoxicitv of v-indesine sulphate (VDS) in normal and TB rats. VDS has been proved to cause hepatotoxicitv in this strain of rat in our laboratory. No evident difference in hepatotoxicitv was observed between the two groups. In other words. the type IV collagenolytic activity did not seem to relate to the hepatotoxicity. We speculate that this was because liver and kidney are histologrically different: liv-er will be less affected by MMP-9 than kidney.
This report proposes the possibility that the effects of anticancer drugs on some normal tissues may be augmented by MMPs originated from tumour cells. Zucker et al (1993) reported that overproduction of MMP-9 occurred in colon cancer and breast cancer in humans. However. this possibility has not been noticed clinically so far. It is certainly feasible. we think. that some of the variability in the nephrotoxicitv of anti-cancer drurs could be due to tumour factors. We should be aware of the side-effects of anticancer drugs when we treat a patient with an MMPs-producing tumour with anti-cancer drugs. 
